Market Size of Endobronchial Ultrasound Biopsy Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.36 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Endobronchial Ultrasound Biopsy Market Analysis
The endobronchial ultrasound biopsy market is poised to witness a CAGR of 4.36% over the forecast period.
Initially, COVID-19 impacted the studied market growth due to the cancellations of elective biopsy procedures and surgical procedures. COVID-19 also had an adverse impact on people with co-morbid conditions such as respiratory diseases. However, the market recovered in the last few years since the restrictions were lifted. COVID-19 has had a negligible impact on the endobronchial ultrasound biopsy market in the current scenario and is expected to register a stable growth rate during the forecast period.
Respiratory disorders such as chronic obstructive pulmonary disorder (COPD), tuberculosis, and lung and bronchus cancer use endobronchial ultrasound biopsy to obtain tissue or fluid samples from the lungs and surrounding lymph nodes without conventional surgery to diagnose and detect the severity of diseases. For instance, according to 2022 statistics published by National Health Science, about 1.17 million people in England were diagnosed with COPD in 2021, accounting for 1.9% of the total population. According to the Australian Bureau of Statistics, March 2022 update, 375.8 thousand individuals (1.5%) of all ages had chronic obstructive pulmonary disease in Australia in 2021. Therefore, the rising burden of such diseases is expected to propel market growth.
Furthermore, according to WHO's October 2022 update, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide in 2021. Endobronchial tuberculosis (EBTB) is an infection of the tracheobronchial tree by Mycobacterium tuberculosis, which is very common in TB. Therefore, a large number of tuberculosis cases worldwide is expected to propel the demand for endobronchial biopsy.
Additionally, the strategic initiatives by market players, such as product launches, partnership, and acquisitions to expand the offerings, contributes significantly to the market growth. For instance, in May 2021, Olympus launched the FDA 510(k)-cleared BF-UC190F endobronchial ultrasound (EBUS) bronchoscope to its EBUS portfolio of devices for minimally invasive lung cancer diagnosis and staging via needle biopsy. The launches of technologically advanced products are expected to boost the demand for such devices during the forecast period.
Therefore, owing to the aforementioned factors, such as the high burden of respiratory diseases and rising product launches by market players, the studied market is anticipated to witness growth over the analysis period. However, the high cost of equipment and lack of reimbursement policies in developing countries are likely to restrain market growth.
